Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisia herb extract (specifically a standardized 95% ethanol extract of *Artemisia argyi* or *Artemisia asiatica*) is a botanical pharmaceutical product developed and marketed by Chong Kun Dang Pharmaceutical under the brand name Arton for the treatment of acute and chronic gastritis. The extract contains active phytochemicals, most notably the flavones eupatilin and jaceosidin, which provide gastroprotective effects. Its primary mechanism involves stimulating the secretion of gastric mucus and increasing the synthesis of endogenous prostaglandins (such as PGE2), which enhance the mucosal barrier against irritants like alcohol, NSAIDs, and stress. Additionally, the extract exhibits anti-inflammatory activity by inhibiting NF-kappaB signaling and antioxidant properties through the scavenging of reactive oxygen species. In the South Korean pharmaceutical market, Artemisia herb extracts are established standards of care for gastritis and are frequently utilized as active comparators in clinical trials for newer mucoprotective agents, such as CKD-495.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artemisia herb extract.